Investment
Features
FeesSafety
Academy
More
Pluang+

Dogecoin needs 80% gain and to break $0.093 resistance to target $0.15 amid whale buying but weak ETF demand

Technical Signals
18 Sep 2026
Coinpaper
View Source
Neutral
Dogecoin needs 80% gain and to break $0.093 resistance to target $0.15 amid whale buying but weak ETF demand

Dogecoin (DOGE) is trading near $0.08 and would need to rise about 80% to reach $0.15. Key resistance lies at $0.093–$0.095, which DOGE must reclaim and sustain to move higher. Whale investors have increased their holdings by over 240 million DOGE recently, signaling some buying interest. However, institutional demand via U.S. DOGE ETFs remains weak, with minimal inflows and one ETF closing soon, making DOGE more reliant on spot buyers and speculative trading. To reach $0.15, DOGE needs stronger whale accumulation, a better Bitcoin market, and renewed meme-coin interest. Support is critical at $0.081–$0.084, and losing this could weaken DOGE's outlook.

Dogecoin price prediction is the subject, with key resistance near $0.093–$0.095. For readers following cryptocurrency markets, here is Pluang's market snapshot as of Sep 18, 2026 21:36 WIB: out of 50 major cryptocurrencies, 46 rose and 3 fell. Notable movers include UNI at Rp157.002 (+21.80%), THETA at Rp3.664 (+12.84%), and BAL at Rp16.297 (+11.14%).

More News

Duke Energy's stock shows 8.26% upside with strong earnings forecast and mixed institutional interest.

Duke Energy's stock shows 8.26% upside with strong earnings forecast and mixed institutional interest.

Duke Energy Corporation's stock is projected to rise about 8.26% to a price target of $127, down slightly from $133, reflecting confidence despite a recent price dip. The company expects a 4.42% increase in earnings per share to $1.89 and a 3.86% ris...

Analyst Insights
Bullish
2 hours ago
Xenon Pharmaceuticals stock plunges 27.6% after pausing clinical trials due to safety concerns.

Xenon Pharmaceuticals stock plunges 27.6% after pausing clinical trials due to safety concerns.

Xenon Pharmaceuticals halted new patient enrollment in its psychiatry clinical trials for the drug azetukalner after reports of neuropsychiatric side effects. This pause led to a sharp 27.6% drop in its stock price, marking its worst day since 2017. ...

Market News
Bearish
3 hours ago
Innate Pharma beats EPS estimates and secures $75M deal with Sobi, boosting cash runway to 2028

Innate Pharma beats EPS estimates and secures $75M deal with Sobi, boosting cash runway to 2028

Innate Pharma reported an EPS of -$0.24, beating analyst estimates of -$0.29, and revenue of $6.5 million, slightly above expectations. The company secured a strategic partnership with Sobi for its drug lacutamab, receiving a $75 million upfront paym...

Company Fundamentals
Bullish
3 hours ago
HYPE token hits new all-time high after Hyperliquid enables manual USDC/USDT borrowing with HYPE and Bitcoin collateral.

HYPE token hits new all-time high after Hyperliquid enables manual USDC/USDT borrowing with HYPE and Bitcoin collateral.

HYPE token surged 10.5% to $91.20, reaching a new all-time high of $92.56 after Hyperliquid launched manual borrowing of USDC and USDT using HYPE and Bitcoin as collateral. The platform offers a 65% loan-to-value ratio for HYPE, higher than Bitcoin's...

Market News
Bullish
4 hours ago
CleanTech hires Mercator for independent report on fluorspar project in Kentucky, advancing critical mineral exploration.

CleanTech hires Mercator for independent report on fluorspar project in Kentucky, advancing critical mineral exploration.

CleanTech Vanadium Mining Corp. has engaged Mercator Geological Services to prepare an independent technical report on its Campbell-Crotser fluorspar project in Kentucky, following National Instrument 43-101 standards. The report will detail geology,...

Company Fundamentals
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App